The indications of IAP0971 include lung cancer, cervical cancer, head and neck squamous cell carcinoma, liver cancer, lymphoma, and other malignant tumors. A Phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of IAP0971 in patients with locally advanced or metastatic malignant tumors is currently on-going (NCT05396391).

1 year ago

PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2 (Interleukin 2) • IL15 (Interleukin 15)

IAP0971

over1year

Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex. (PubMed, Antib Ther)

IAP0971 has demonstrated a favorable safety profile and potent anti-tumor activities in vivo. A Phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of IAP0971 in patients with advanced malignant tumors is on-going (NCT05396391).

over 1 year ago

Preclinical • Journal

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2 (Interleukin 2) • IL15 (Interleukin 15)

IAP0971

almost2years

A Phase I/IIa Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)

P1/2, N=140, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.

almost 2 years ago

New P1/2 trial

PD-L1 (Programmed death ligand 1)

PD-L1 expression

IAP0971